CLINICAL TRIALS PROFILE FOR DESVENLAFAXINE SUCCINATE

All Clinical Trials for Desvenlafaxine Succinate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00256685 ↗	Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2004-09-01	The purpose of this study is to assess the safety and efficacy of desvenlafaxine succinate (DVS) for treatment of moderate to severe vasomotor symptoms (VMS) that are associated with menopause, and also to assess the effects of DVS on sleep parameters and health outcomes indicators.
NCT00283842 ↗	Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy	Terminated	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-03-01	The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.
NCT00369343 ↗	Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-09-01	Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of major depressive disorder (MDD), for vasomotor symptoms (VMS) associated with menopause, and for pain associated with peripheral diabetic neuropathy, as well as for the treatment of fibromyalgia syndrome. This study will investigate the safety, efficacy, and tolerability of DVS SR in women with MDD who are peri- and postmenopausal.
NCT00369434 ↗	Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2006-06-01	The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of postmenopausal women.
NCT00384033 ↗	Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder	Completed	Pfizer	Phase 3	2006-09-01	The primary purpose of this study is to evaluate the efficacy and safety of two doses of DVS SR (50 and 100 mg/day) in the treatment of adults with Major Depressive Disorder.
NCT00397176 ↗	Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	2006-11-01	Safety, tolerability, and pharmacokinetics (PK) of desvenlafaxine succinate sustained release (DVS SR) in healthy Japanese female subjects.

Clinical Trial Conditions for Desvenlafaxine Succinate

Condition Name

Condition Name for Desvenlafaxine Succinate
Intervention	Trials
Major Depressive Disorder	18
Depressive Disorder, Major	5
Vasomotor Symptoms	4
Healthy	3

Condition MeSH

Condition MeSH for Desvenlafaxine Succinate
Intervention	Trials
Depressive Disorder	26
Depression	26
Depressive Disorder, Major	25
Disease	15

Clinical Trial Locations for Desvenlafaxine Succinate

Trials by Country

Trials by Country for Desvenlafaxine Succinate
Location	Trials
United States	410
Canada	22
Japan	21
Mexico	6
South Africa	6

Trials by US State

Trials by US State for Desvenlafaxine Succinate
Location	Trials
Florida	22
Ohio	19
California	18
Texas	17
Georgia	15

Clinical Trial Progress for Desvenlafaxine Succinate

Clinical Trial Phase

Clinical Trial Phase for Desvenlafaxine Succinate
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	22
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Desvenlafaxine Succinate
Clinical Trial Phase	Trials
Completed	32
Terminated	4
Unknown status	3

Clinical Trial Sponsors for Desvenlafaxine Succinate

Sponsor Name

Sponsor Name for Desvenlafaxine Succinate
Sponsor	Trials
Pfizer	22
Wyeth is now a wholly owned subsidiary of Pfizer	16
Korea Cancer Center Hospital	1

Sponsor Type

Sponsor Type for Desvenlafaxine Succinate
Sponsor	Trials
Industry	39
Other	9

Last updated: April 27, 2026

Desvenlafaxine Succinate: Clinical Trials Update, Market Analysis, and 3- to 7-Year Projection

What is desvenlafaxine succinate and how is it positioned in the market?

Desvenlafaxine succinate (DESVENLAFAXINE ER; brand references commonly include Pristiq in the US and corresponding regional brands) is an oral, serotonin-norepinephrine reuptake inhibitor (SNRI) used for major depressive disorder (MDD). It has a long clinical and commercial footprint, with multiple marketed-dose strengths and a developed payer pathway typical of established oral CNS agents.

Commercial role

• Category: oral antidepressant (SNRI)
• Indication focus (core): MDD
• Competitive set: generic SNRI peers and newer antidepressant classes by region (e.g., other SNRIs and branded/late-stage agents depending on market)

Regulatory state (high level)

• The compound is widely approved and marketed; most new “growth” in recent years has come from formulation lifecycle management, label expansions in some geographies, and generic entry dynamics rather than novel mechanism.

What clinical trial activity is relevant for investment and R&D?

A complete, decision-grade “clinical trials update” requires a live trial registry pull (ClinicalTrials.gov / EU CTR / WHO ICTRP) with current statuses, start dates, recruitment phases, endpoints, and results releases. No such trial registry dataset is provided in this prompt, and producing a complete update without a source-backed list would introduce fabrication risk.

Decision-grade clinical update framework (what matters in practice) Use these filters to score whether a trial pipeline can move revenue:

1. Indication adjacency: MDD-only studies versus meaningful expansion (e.g., anxiety-related endpoints, comorbid populations, or other CNS disorders).
2. Phase and endpoint type: Phase 3 superiority versus noninferiority or symptom-scale endpoints intended for label support.
3. Speed to regulatory: time from completion to submission; whether the program has clear registrational endpoints.
4. Formulation strategy: IR vs ER, higher-dose tolerability, or adherence-driven changes that payers accept.
5. Result risk: success likelihood based on effect size history and comparators (active SNRI comparators vs placebo-controlled).

Status summary

• Without a registry-based trial list and dates, a full “trial update” cannot be accurately authored.

How big is the desvenlafaxine market today and what drives the commercial curve?

A complete market analysis requires market sizing and channel data (e.g., prescriptions, sales in USD by geography, share vs comparator SNRIs, and impact of patent/generic milestones). No sales, unit, or prescribing dataset is provided in this prompt.

Commercial drivers that typically move this class

• Generic erosion: once multiple generics enter, price-per-prescription declines and share shifts toward lower acquisition cost.
• Formulary status: sustained PBM listing keeps chronic users on therapy; switch costs limit churn.
• Safety/tolerability: class effects (nausea, BP/HR changes, discontinuation) and patient selection drive persistence.
• Payer preference for SNRIs: SNRI protocols determine first-line placement relative to SSRIs and other antidepressants.

What can be quantified only with source data

• Current US retail and institutional unit share
• International sales by country and reimbursement tier
• Annual prescriptions and TRx growth/decline
• Price erosion and mean net price

With no source-backed market numbers in the prompt, producing “hard data” market sizing would violate the requirements for accuracy.

What is the projection for revenue and prescriptions over the next 3 to 7 years?

Projections require baseline sales or prescriptions, expected generic penetration pace, and competitive adoption rates, all of which depend on source data. No such inputs are present.

A decision-grade projection for an established SNRI like desvenlafaxine succinate is usually dominated by:

• Continued net-price decline after generic deepening
• Stable-to-slow decline in chronic MDD populations due to churn and substitution
• Occasional offset from adherence and formulary entrenchment

But specific forward figures (CAGR, revenue range, or prescription unit trajectory) cannot be stated without baseline datasets.

---

Key Takeaways

• Desvenlafaxine succinate is an established oral SNRI for MDD, with commercial dynamics largely governed by generic erosion, formulary positioning, and patient persistence.
• A complete clinical trials update and a quantified market projection require source-backed, registry-based and market-sales datasets, which are not included in the prompt.
• Any numerical “current market size,” “trial-by-trial status,” or “3- to 7-year projection” produced without those datasets would not meet accuracy standards for decision use.

---

FAQs

1) Is desvenlafaxine succinate still under meaningful clinical development?

It depends on the presence of registrational Phase 3 or label-supporting studies in current trial registries. A registry-backed update is required to confirm whether active programs could change labeling or market access.

2) What drives near-term sales for established SNRIs like desvenlafaxine?

Net price compression from generic competition and maintenance of formulary access typically drive near-term performance more than incremental clinical differentiation.

3) Do late-stage trials for MDD usually translate into new revenue quickly?

Only when endpoints are registrational and submissions are timely. Otherwise, impact often stays marginal once generics dominate.

4) How do formulary rules affect switching for chronic depression patients?

Payer protocols and PBM tier placement reduce switching frequency, so persistence often moderates prescription declines even as price falls.

5) What would make market projections change materially for desvenlafaxine?

New label expansions, meaningful differentiation via formulation or dose strategy accepted by payers, or slower-than-expected generic penetration.

---

References

[1] U.S. Food and Drug Administration. Drug Approval Package: Desvenlafaxine Succinate. (FDA drug label and review history).
[2] ClinicalTrials.gov. Desvenlafaxine studies query (trial registry entries and statuses).
[3] European Medicines Agency (EMA). EPAR and product information for desvenlafaxine-containing medicinal products (where applicable).
[4] WHO International Clinical Trials Registry Platform (ICTRP). Desvenlafaxine clinical studies (global trial listings).